Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
Webster et al. • 2017 • Br J Pharmacol. 2017;174(5):396-408.
© 2024 Corcept Therapeutics, Incorporated
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer
Veneris et al • 2017 • Gynecol Oncol.